Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics
Galvez, L.; Rusz, M.; Schwaiger-Haber, M.; et al.
Oxaliplatin is a chemotherapy drug administered to aid treatment of metastatic colorectal cancer. Despite its regularity, the impact of this metallodrug on drug uptake/distribution and the metabolome remains unclear. In an effort to address this, Koellensperger and colleagues developed an integrated metallomics/metabolomics method for evaluating sensitive/resistant human colon cancer cell models. This approach involved adding a U-13C metabolite yeast extract (ISO1) at the extraction stage for normalization and improved repeatability, with split analysis for platinum (by ICP-MS) and metabolite (by HILIC-MS/MS) measurement. The combined results shed light on oxaliplatin resistance mechanisms, with future studies needed to investigate the effects of inhibiting fatty acid oxidation on drug sensitivity/resistance.
Articles
- SILAC quantitative proteomics and biochemical analyses reveal a novel molecular mechanism by which ADAM12S promotes the proliferation, migration, and invasion of small cell lung cancer cells through upregulating hexokinase 1
- Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics
- Leucine co-ingestion augments the muscle protein synthetic response to the ingestion of 15 g protein following resistance exercise in older men
- Assessment of methylcitrate and methylcitrate to citrate ratio in dried blood spots as biomarkers for inborn errors of propionate metabolism
- Metabolomics and isotope tracing
